Welcome to our dedicated page for Innovate news (Ticker: VATE), a resource for investors and traders seeking the latest updates and insights on Innovate stock.
INNOVATE Corp. reports developments across a diversified portfolio organized around Infrastructure, Life Sciences and Spectrum. News commonly covers consolidated earnings, subsidiary performance, DBM Global cash dividends, steel construction activity, Spectrum network and broadcasting updates, and capital or operating developments within portfolio companies.
Life Sciences updates center on MediBeacon, an equity method investment developing fluorescent tracer agents and transdermal detection for kidney function assessment through the TGFR System, including FDA, NMPA and CE Mark regulatory milestones. INNOVATE also reports R2 system sales and commercial agreements as part of its portfolio-company operating updates.
INNOVATE Corp. (NYSE: VATE) announced the successful completion of the sale of its 19% interest in HMN International Co. Ltd. to affiliates of Hengtong Optic-Electric Co Ltd. This transaction, initiated through a supplemental agreement in June 2022, will net INNOVATE approximately $32 million after taxes and fees. The funds are earmarked for reinvestment, debt repayment, and general working capital, enhancing the company's balance sheet flexibility. CEO Wayne Barr, Jr. highlighted that the proceeds will support the development of their innovative operating businesses aimed at sustainable growth and value creation.
On March 2, 2023, INNOVATE Corp. (NYSE: VATE) announced a rescheduling of its fourth quarter and full year 2022 earnings release to March 14, 2023, after market close. The earnings conference call will take place on the same day at 4:30 p.m. ET, focusing on the results, operations, and strategy of the company. INNOVATE operates in infrastructure, life sciences, and spectrum sectors, employing approximately 3,902 people across its subsidiaries.
INNOVATE Corp. (NYSE: VATE) announced it will release its financial results for Q4 and full year 2022 on March 8, 2023, after market close. The company will host an earnings conference call at 4:30 p.m. ET on the same day to discuss the results, operations, and strategy. Interested parties can access the call via the Investor Relations website, with dial-in options available for domestic and international participants. A replay will be provided post-call until March 22, 2023. For further details, visit www.INNOVATECorp.com.
Catalent, Inc. (NYSE: CTLT) has appointed Joseph A. Ferraro as its Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary, based in Somerset, New Jersey. Mr. Ferraro brings extensive experience from his tenure at Innovate Corp. (NYSE: VATE) and Prospect Capital (NASDAQ: PSEC), where he managed global legal and compliance operations, including significant M&A transactions. He will lead Catalent's legal and compliance teams and report to Steven Fasman, Chief Administrative Officer. This strategic appointment is expected to enhance Catalent's legal oversight as it navigates the highly regulated life sciences market.
MediBeacon Inc. has made significant strides in its Phase 3 study aimed at kidney disease, announcing amendments to its partnership with Huadong Medicine. This includes $10 million in funding through Q2 2023, with a milestone payment of $7.5 million contingent on FDA approval of the MediBeacon® TGFR Measurement System. The device measures Glomerular Filtration Rate non-invasively and has been designated as a Breakthrough Device by the FDA. The company has submitted three of five required PMA modules, moving closer to FDA approval.
INNOVATE Corp. (NYSE: VATE) reported a 7.1% increase in revenue to $423.0 million for Q3 2022, driven by its Infrastructure segment, which saw strong demand. The company achieved a remarkable 96.9% reduction in net loss to $6.6 million from $213.0 million, reflecting improved performance across its segments. Adjusted EBITDA rose by 14.7% to $16.4 million. The total backlog stood at $1.9 billion, while the company received a notice from the NYSE regarding continued listing standards compliance.
INNOVATE Corp. (NYSE: VATE) will release its third quarter 2022 financial results on November 2, 2022, after market close. A conference call to discuss these results, along with operational insights and strategic initiatives, is scheduled for the same day at 4:30 p.m. ET. Interested parties can participate via phone or listen to the live broadcast on the company’s Investor Relations website. Call-in details include a domestic dial-in number of 1-877-300-8521 and an international option of 1-412-317-6026. A replay will be available until November 16, 2022.
INNOVATE Corp. (NYSE: VATE) reported a significant revenue increase of 60.9% year-over-year, reaching $392.2 million in Q2 2022, driven primarily by its Infrastructure segment. The company also noted an 86.2% rise in Total Adjusted EBITDA, totaling $12.1 million. Despite a net loss of $13.6 million, improved performance at DBM Global and MediBeacon's FDA acceptance for its kidney monitoring technology highlighted the company's potential. However, Spectrum's revenue fell by 14.2%, reflecting challenges in advertising and programming.
INNOVATE Corp. (NYSE: VATE) announced the appointment of Amy Wilkinson to its Board of Directors, aiming to enhance shareholder value across its Infrastructure, Life Sciences, and Spectrum segments. Wilkinson, a consultant to Fortune 500 firms and founder of Ingenuity, brings extensive management and global business expertise. Her previous roles include White House Fellow and positions at McKinsey & Company. The Board now consists of five members, with four being independent.
INNOVATE Corp. (NYSE: VATE) will release its Q2 2022 financial results on August 3, 2022, after market close. An earnings conference call is scheduled for the same day at 4:30 p.m. ET, during which the Company will discuss its financial performance and strategic operations. The call can be accessed through the Company’s Investor Relations website, with specific dial-in instructions provided for both live participation and replay. INNOVATE is focused on stakeholder capitalism and operates in key areas including Infrastructure, Life Sciences, and Spectrum.